Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
Malolan Sri Rajagopalan, Dwight Earl Heron, Rodney E. Wegner et al. · Radiation Oncology · 2013
BACKGROUND: Neoadjuvant stereotactic body radiotherapy (SBRT) has potential applicability in the management of borderline resectable and locally-advanced pancreatic adenocarcinoma. In this series, we report the pathologic outcomes in the subset of patients who underwent surgery after neoadjuvant SBRT. METHODS: Patients with borderline resectable or locally-advanced pancreatic adenocarcinoma who were treated with SBRT followed by resection were included. Chemotherapy was to the discretion of the medical oncologist and preceded SBRT for most patients. RESULTS: Twelve patients met inclusion criteria. Most (92%) received neoadjuvant chemotherapy, and gemcitabine/capecitabine was most frequently utilized (n = 7). Most were treated with fractionated SBRT to 36 Gy/3 fractions (n = 7) and the remainder with single fraction to 24 Gy (n = 5). No grade 3+ acute toxicities attributable to SBRT were found. Two patients developed post-surgical vascular complications and one died secondary to this. The mean time to surgery after SBRT was 3.3 months. An R0 resection was performed in 92% of patients (n = 11/12). In 25% (n = 3/12) of patients, a complete pathologic response was achieved, and an additional 16.7% (n = 2/12) demonstrated <10% viable tumor cells. Kaplan-Meier estimated median progression free survival is 27.4 months. Overall survival is 92%, 64% and 51% at 1-, 2-, and 3-years. CONCLUSIONS: This study reports the pathologic response in patients treated with neoadjuvant chemotherapy and SBRT for borderline resectable and locally-advanced pancreatic cancer. In our experience, 92% achieved an R0 resection and 41.7% of patients demonstrated either complete or extensive pathologic response to treatment. The results of a phase II study of this novel approach will be forthcoming.
Cited by 69 works. doi:10.1186/1748-717x-8-254 Open-access PDF
Authors
- Malolan Sri Rajagopalan
- Dwight Earl Heron
- Rodney E. Wegner
- Herbert J. Zeh
- Nathan Bahary
- Alyssa M. Krasinskas
- Barry C. Lembersky
- Randall E. Brand
- Arthur James Moser
- Annette E. Quinn
- Steven A. Burton
References
- Cancer statistics, 2012
- Pancreatic Cancer
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
- Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas
- Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma